The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis

• Published in: Clinical genitourinary cancer 2024-04, Vol.22 (2), p.610-617.e1
• Main Authors: Brink, Luna van den, Ruiter, Annebeth E. C., Lagerveld, Brunolf W., Graafland, Niels M., Bex, Axel, Beerlage, Harrie P., van Moorselaar, Jeroen R. A., Zondervan, Patricia J.
• Format: Article
• Language: English
• Subjects: Carcinoma, Renal Cell - therapy; Decision Making; Decision Making, Shared; Humans; Kidney Neoplasms - therapy; Multidisciplinary tumor board; Prospective Studies; Renal cell carcinoma; Shared decision making
• ISSN: 1558-7673; 1938-0682
• DOI: 10.1016/j.clgc.2024.01.021

To describe the impact of a multidisciplinary tumor board (MTB) for renal cell carcinoma (RCC) patients in a locoregional renal cancer network by evaluating shared decision making (SDM) and adherence to MTB recommendations. This prospective cohort study included all cases from a Dutch renal cancer network with suspicion of or histologically confirmed RCC discussed in MTBs between 2017-2022. Main endpoints were distribution of cases presented, proportion of recommendations with multiple treatment options enabling shared decision making (SDM), definite treatment after SDM and adherence to MTB recommendations. Further endpoints were definite treatment per tumor stage stratified by age and inclusion in clinical trials. Outcomes were displayed as means and proportions (%). Pearson's Chi-Squared test was used to analyze the effect of age on definite treatment advice. Overall, 2651 cases were discussed, of which 1900 (72%) were new referrals and 751 (28%) rediscussions. Majority of cases were cT1a-b tumors (46%) and 22% were local recurrences or metachronous metastatic. Adherence to MTB recommendation was 96% and in 30% multiple treatment options were recommended, allowing for SDM. In 45% of cases with cT1a tumors multiple treatment options were recommended by the MTB, resulting in (cryo)ablation (32%) and AS (30%) as most frequent definite treatments after SDM. Among patients with cT3-4 tumors the inclusion rate in clinical trials was 47%. A network MTB creates opportunity to discuss multiple treatment options and clinical trials in SDM with patients at a high rate of adherence to MTB recommendation. This study describes the impact of a multidisciplinary tumor board (MTB) for renal cell carcinoma (RCC) patients in a locoregional renal cancer network by evaluating shared decision making and adherence to MTB recommendations. Adherence to MTB recommendation was high (96%) and in 30% multiple treatment options were recommended, allowing for shared decision making with the patient.